NCT01928680Unknown2 期
Phase II Study of Capecitabine and Cisplatin in Anthracycline and Taxanes-pretreated Metastatic Triple Negative Breast Cancer Patients
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- Overall Response Rate
研究概览
简要总结
It is a phase II trial to explore the efficacy and safety of cisplatin plus capecitabine in anthracycline and taxane-pretreated metastatic triple negative breast cancer patients.
详细描述
Cisplatin contained regimens have been demonstrated to be effective in metastatic triple negative breast cancer patients in some phase II clinical trials. Meanwhile, Capecitabine is also a highly effective choice for metastatic breast cancer with considerable duration of response. Combination of cisplatin and capecitabine have been proved effective in metastatic breast cancer in several phase II trials. This study is aimed to investigate the efficacy and safety of this combination in triple negative breast cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Written and signed informed consent prior to beginning specific protocol procedures.
- •Pathologically confirmed Estrogen Receptor(ER), Progesterone Receptor(PR) and Human Epidermal growth factor Receptor HER-2) negative ("triple negative") breast cancer and documented metastatic or locally advanced disease.
- •Measurable disease - with at least 1 lesion measurable by radiological method
- •18 to 70 years old women
- •Previously treated with an anthracycline and a taxane
- •Hormone therapy for early-stage or metastatic breast cancer was permitted if hormonal receptor positive.
- •Treatment with Herceptin for early-stage or metastatic breast cancer is permitted if HER2 positive
- •Laboratory requirements:
- •Hematology Absolute neutrophil count>=1,500 /μl; Platelets>=100,000 /μl; Hemoglobin>=10 g/dl
- •Liver function Total bilirubin<=2 times ULN ASAT (SGOT) and ALAT (SGPT)<=2.5 times UNL without liver metastasis or <=5.0 times if liver metastasis Glucose<=200 mg/dL
- •Renal function Serum creatinine<=140 mol/l
- •Life expectancy of at least 12 weeks
- •Patients must be accessible for treatment and follow-up.
- •Patients should have recovered from the acute reversible effects of prior treatment. This generally means at least 3 weeks should have elapsed since prior chemotherapy, adjuvant or Neoadjuvant treatment. and at least 4 weeks since prior (radical) radiotherapy or major surgery
排除标准
- •Women who are pregnant or breast feeding
- •History of brain and/or leptomeningeal metastases
- •Past or current history of malignant neoplasm other than breast carcinoma, except for curatively treated non melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years
- •Pre-existing neuropathy grade 1 according to the NCIC-CTC 3.0
- •Psychiatric disorders or other conditions which would prevent pt. compliance
- •Other serious illness or medical condition:
- •Congestive heart failure, or unstable angina pectoris, previous history of myocardial infarction within 6 month prior to study entry, uncontrolled hypertension as determined by the Investigator or high risk uncontrolled, arrhythmia.
- •History of significant neurological or psychiatric disorders including psychotic disorders, dementia of seizures that would prohibit the understanding and giving of informed consent.
- •Active uncontrolled infection.
- •Unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of Corticosteroids.
- •Inability to take and/or absorb oral medicine
- •Prior treatment with capecitabine and/or cisplatin
- •Concurrent treatment with other experimental drugs, or participation in another clinical trial with any investigational drug within 30 days prior to study entry
研究组 & 干预措施
Cisplatin/Capecitabine
Experimental
Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity.
This is a single arm phase II clinical trial.
干预措施: Cisplatin/Capecitabine (Drug)
结局指标
主要结局
Overall Response Rate
时间窗: 6 months
次要结局
- Progression Free Survival(2 years)
- Number and Severity of Adverse Events of Patients Enrolled in This Trial(1 year)
- Overall Survival(3 years)
研究者
Li Qiao
MD
Chinese Academy of Medical Sciences
研究点 (1)
Loading locations...
相似试验
终止
2 期
First-Line Capecitabine and Cetuximab for Metastatic Colorectal Ca in Elderly PatientsColorectal CancerNCT00251186University of Medicine and Dentistry of New Jersey18
已完成
2 期
Capecitabine and Tipifarnib in Treating Women With Taxane-Resistant Metastatic Breast CancerRecurrent Breast CancerStage IV Breast CancerNCT00077363National Cancer Institute (NCI)70
已完成
2 期
A Phase II study of capecitabine plus cisplatin (plustrastuzumab) for previously untreated advanced gastric cancer.untreated advanced gastric cancerJPRN-UMIN000006458Ehime University45
已完成
2 期
A Phase II study of capecitabine plus cisplatin (plus trastuzumab) for previously untreated advanced gastric cancer.untreated advanced gastric cancerJPRN-UMIN000005998Department of Digestive surgery, Kawasaki Medical University53
Unknown
2 期
XParTS: Capecitabine/Cisplatin(XP) for Recurrent Gastric CancerGastric CancerNCT01412294Epidemiological and Clinical Research Information Network40